At the core of Seattle Genetics are human antibodies. The company studies, manipulate and finally packages drugs. In the company’s capability of connecting to other things is where their power lies. The cancer cell is destroyed from within by the toxins released from the antibody. Seattle Genetics is ranked the largest biotech in Washington. It has a workforce of 900 employees and a market value of approximately 10 billion dollars. It has also heavily invested in research and marketing in a bid to graduate from a biotech company to a pharmaceutical firm.
Seattle Genetics’ leading drug, Adcetris, treats Hodgkin lymphoma and its sales could begin if the tests being undertaken come out positive. The company’s CEO, Clay Siegall, cites that it is an emerging global, multiproduct and oncology company. The numerous drugs are evidence of his ambitions to grow the company to something greater. Siegall offered 2 billion dollars to acquire global rights that would enable him to commercialize the cancer drug that was developed by a New Jersey immunomedics. The deal however never went through after Clay retreated after a judge’s ruling.
With 46 percent growth from 2014, Seattle Genetics made sales of around 418 million dollars in 2016. Its stock prices have grown more than thrice within five years. It has mainly concentrated on a drug known as an antibody-drug conjugate which targets antigens. According to Siegall of their 11 drugs, 4 have a higher probability of immediate sales. The first is Adcetris; second is 33A, 22ME and lastly LIV1 which targets breast cancer. Despite the political and economic climate, Seattle remains stable.
Founder, President, and CEO of Seattle Genetics Clay Siegall is a graduate who pursued a degree leading to BSc in Zoology from the University Of Maryland. In 1998 Clay Siegall co-founded Seattle Genetics. He was awarded a Ph.D. in Genetics from George Washington University. Under his supervision, Seattle Genetics has been able to diversify and build antibody-based cancer therapies and acquire over 675 million dollars through private and public financings.
Before co-founding Seattle Genetics, Dr. Clay was working with the National Institutes of Health. From 1991 to 1997 he worked with the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. In Alder BioPharmaceuticals and Mirna Therapeutics, Clay is a member of the Board of Directors. At Fred Hutchinson Cancer Research Centre he is on the Board of Governors. He has not only authored over 70 publications, but he also holds 15 patents.